Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO)

Julie Lecarpentier, Catherine Noguès, Emmanuelle Mouret-Fourme, Marion Gauthier-Villars, Christine Lasset, Jean-Pierre Fricker, Olivier Caron, Dominique Stoppa-Lyonnet, Pascaline Berthet, Laurence Faivre, Valérie Bonadona, Bruno Buecher, Isabelle Coupier, Laurence Gladieff, Paul Gesta, François Eisinger, Marc Frénay, Elisabeth Luporsi, Alain Lortholary, Chrystelle Colas, Catherine Dugast, Michel Longy, Pascal Pujol, Julie Tinat, GENEPSO, Rosette Lidereau, Nadine Andrieu, Julie Lecarpentier, Catherine Noguès, Emmanuelle Mouret-Fourme, Marion Gauthier-Villars, Christine Lasset, Jean-Pierre Fricker, Olivier Caron, Dominique Stoppa-Lyonnet, Pascaline Berthet, Laurence Faivre, Valérie Bonadona, Bruno Buecher, Isabelle Coupier, Laurence Gladieff, Paul Gesta, François Eisinger, Marc Frénay, Elisabeth Luporsi, Alain Lortholary, Chrystelle Colas, Catherine Dugast, Michel Longy, Pascal Pujol, Julie Tinat, GENEPSO, Rosette Lidereau, Nadine Andrieu

Abstract

Introduction: Mutations in BRCA1 and BRCA2 confer a high risk of breast cancer (BC), but the magnitude of this risk seems to vary according to the study and various factors. Although controversial, there are data to support the hypothesis of allelic risk heterogeneity.

Methods: We assessed variation in BC risk according to factors related to pregnancies by location of mutation in the homogeneous risk region of BRCA1 and BRCA2 in 990 women in the French study GENEPSO by using a weighted Cox regression model.

Results: Our results confirm the existence of the protective effect of an increasing number of full-term pregnancies (FTPs) toward BC among BRCA1 and BRCA2 mutation carriers (≥3 versus 0 FTPs: hazard ratio (HR) = 0.51, 95% confidence interval (CI) = 0.33 to 0.81). Additionally, the HR shows an association between incomplete pregnancies and a higher BC risk, which reached 2.39 (95% CI = 1.28 to 4.45) among women who had at least three incomplete pregnancies when compared with women with zero incomplete pregnancies. This increased risk appeared to be restricted to incomplete pregnancies occurring before the first FTP (HR = 1.77, 95% CI = 1.19 to 2.63). We defined the TMAP score (defined as the Time of Breast Mitotic Activity during Pregnancies) to take into account simultaneously the opposite effect of full-term and interrupted pregnancies. Compared with women with a TMAP score of less than 0.35, an increasing TMAP score was associated with a statistically significant increase in the risk of BC (P trend = 0.02) which reached 1.97 (95% CI = 1.19 to 3.29) for a TMAP score >0.5 (versus TMAP ≤0.35). All these results appeared to be similar in BRCA1 and BRCA2. Nevertheless, our results suggest a variation in BC risk associated with parity according to the location of the mutation in BRCA1. Indeed, parity seems to be associated with a significantly decreased risk of BC only among women with a mutation in the central region of BRCA1 (low-risk region) (≥1 versus 0 FTP: HR = 0.27, 95% CI = 0.13 to 0.55) (Pinteraction <10-3).

Conclusions: Our findings show that, taking into account environmental and lifestyle modifiers, mutation position might be important for the clinical management of BRCA1 and BRCA2 mutation carriers and could also be helpful in understanding how BRCA1 and BRCA2 genes are involved in BC.

References

    1. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J. et al.Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;14:1117–1130. doi: 10.1086/375033.
    1. Parsa P, Parsa B. Effects of reproductive factors on risk of breast cancer: a literature review. Asian Pac J Cancer Prev. 2009;14:545–550.
    1. National Breast and Ovarian Cancer Centre. Breast cancer risk factors, a review of the evidence. Australian Government, Cancer Australia. 2009.
    1. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet. 2002;14:187–195.
    1. Newcomb PA, Storer BE, Longnecker MP, Mittendorf R, Greenberg ER, Willett WC. Pregnancy termination in relation to risk of breast cancer. JAMA. 1996;14:283–287. doi: 10.1001/jama.1996.03530280035033.
    1. Brind J, Chinchilli VM, Severs WB, Summy-Long J. Induced abortion as an independent risk factor for breast cancer: a comprehensive review and meta-analysis. J Epidemiol Community Health. 1996;14:481–496. doi: 10.1136/jech.50.5.481.
    1. Wingo PA, Newsome K, Marks JS, Calle EE, Parker SL. The risk of breast cancer following spontaneous or induced abortion. Cancer Causes Control. 1997;14:93–108. doi: 10.1023/A:1018443507512.
    1. Zografos GC, Panou M, Panou N. Common risk factors of breast and ovarian cancer: recent view. Int J Gynecol Cancer. 2004;14:721–740. doi: 10.1111/j.1048-891X.2004.14503.x.
    1. Daling JR, Brinton LA, Voigt LF, Weiss NS, Coates RJ, Malone KE, Schoenberg JB, Gammon M. Risk of breast cancer among white women following induced abortion. Am J Epidemiol. 1996;14:373–380. doi: 10.1093/oxfordjournals.aje.a008938.
    1. Beral V, Bull D, Doll R, Peto R, Reeves G. Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83 000 women with breast cancer from 16 countries. Lancet. 2004;14:1007–1016.
    1. Palmer JR, Wise LA, Adams-Campbell LL, Rosenberg L. A prospective study of induced abortion and breast cancer in African-American women. Cancer Causes Control. 2004;14:105–111.
    1. Mahue-Giangreco M, Ursin G, Sullivan-Halley J, Bernstein L. Induced abortion, miscarriage, and breast cancer risk of young women. Cancer Epidemiol Biomarkers Prev. 2003;14:209–214.
    1. Andrieu N, Goldgar DE, Easton DF, Rookus M, Brohet R, Antoniou AC, Peock S, Evans G, Eccles D, Douglas F, Nogues C, Gauthier-Villars M, Chompret A, Van Leeuwen FE, Kluijt I, Benitez J, Arver B, Olah E, Chang-Claude J. Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS) J Natl Cancer Inst. 2006;14:535–544. doi: 10.1093/jnci/djj132.
    1. Friedman E, Kotsopoulos J, Lubinski J, Lynch HT, Ghadirian P, Neuhausen SL, Isaacs C, Weber B, Foulkes WD, Moller P, Rosen B, Kim-Sing C, Gershoni-Baruch R, Ainsworth P, Daly M, Tung N, Eisen A, Olopade OI, Karlan B, Saal HM, Garber JE, Rennert G, Gilchrist D, Eng C, Offit K, Osborne M, Sun P, Narod SA. Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res. 2006;14:R15. doi: 10.1186/bcr1387.
    1. Jernstrom H, Lerman C, Ghadirian P, Lynch HT, Weber B, Garber J, Daly M, Olopade OI, Foulkes WD, Warner E, Brunet JS, Narod SA. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet. 1999;14:1846–1850. doi: 10.1016/S0140-6736(99)04336-6.
    1. Tryggvadottir L, Olafsdottir EJ, Gudlaugsdottir S, Thorlacius S, Jonasson JG, Tulinius H, Eyfjord JE. BRCA2 mutation carriers, reproductive factors and breast cancer risk. Breast Cancer Res. 2003;14:R121–R128. doi: 10.1186/bcr619.
    1. Lee E, Ma H, McKean-Cowdin R, Van Den BD, Bernstein L, Henderson BE, Ursin G. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study. Cancer Epidemiol Biomarkers Prev. 2008;14:3170–3178. doi: 10.1158/1055-9965.EPI-08-0396.
    1. Jernstrom H, Lubinski J, Lynch HT, Ghadirian P, Neuhausen S, Isaacs C, Weber BL, Horsman D, Rosen B, Foulkes WD, Friedman E, Gershoni-Baruch R, Ainsworth P, Daly M, Garber J, Olsson H, Sun P, Narod SA. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2004;14:1094–1098. doi: 10.1093/jnci/djh211.
    1. Kotsopoulos J, Lubinski J, Lynch HT, Klijn J, Ghadirian P, Neuhausen SL, Kim-Sing C, Foulkes WD, Moller P, Isaacs C, Domchek S, Randall S, Offit K, Tung N, Ainsworth P, Gershoni-Baruch R, Eisen A, Daly M, Karlan B, Saal HM, Couch F, Pasini B, Wagner T, Friedman E, Rennert G, Eng C, Weitzel J, Sun P, Narod SA, Garber J. et al.Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2007;14:221–228. doi: 10.1007/s10549-006-9441-3.
    1. Hartge P, Chatterjee N, Wacholder S, Brody LC, Tucker MA, Struewing JP. Breast cancer risk in Ashkenazi BRCA1/2 mutation carriers: effects of reproductive history. Epidemiology. 2002;14:255–261. doi: 10.1097/00001648-200205000-00004.
    1. Rebbeck TR, Wang Y, Kantoff PW, Krithivas K, Neuhausen SL, Godwin AK, Daly MB, Narod SA, Brunet JS, Vesprini D, Garber JE, Lynch HT, Weber BL, Brown M. Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res. 2001;14:5420–5424.
    1. Milne RL, Osorio A, Cajal T, Baiget M, Lasa A, Diaz-Rubio E, de la Hoya M, Caldes T, Teule A, Lazaro C, Blanco I, Balmana J, Sanchez-Olle G, Vega A, Blanco A, Chirivella I, Esteban CE, Duran M, Velasco E, Martinez de Duenas E, Tejada MI, Miramar MD, Calvo MT, Guillen-Ponce C, Salazar R, San Roman C, Urioste M, Benitez J. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2010;14:221–232. doi: 10.1007/s10549-009-0394-1.
    1. Cullinane CA, Lubinski J, Neuhausen SL, Ghadirian P, Lynch HT, Isaacs C, Weber B, Moller P, Offit K, Kim-Sing C, Friedman E, Randall S, Pasini B, Ainsworth P, Gershoni-Baruch R, Foulkes WD, Klijn J, Tung N, Rennert G, Olopade O, Couch F, Wagner T, Olsson H, Sun P, Weitzel JN, Narod SA. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer. 2005;14:988–991. doi: 10.1002/ijc.21273.
    1. Russo J, Russo IH. Development of the human breast. Maturitas. 2004;14:2–15. doi: 10.1016/j.maturitas.2004.04.011.
    1. Russo J, Russo IH. Cellular basis of breast cancer susceptibility. Oncol Res. 1999;14:169–178.
    1. Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder BA, Stratton MR, Easton D. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet. 1997;14:103–105. doi: 10.1038/ng0197-103.
    1. Thompson D, Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet. 2001;14:410–419. doi: 10.1086/318181.
    1. Thompson D, Easton D. Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev. 2002;14:329–336.
    1. Lubinski J, Phelan CM, Ghadirian P, Lynch HT, Garber J, Weber B, Tung N, Horsman D, Isaacs C, Monteiro AN, Sun P, Narod SA. Cancer variation associated with the position of the mutation in the BRCA2 gene. Fam Cancer. 2004;14:1–10.
    1. Lecarpentier J, Nogues C, Mouret-Fourme E, Stoppa-Lyonnet D, Lasset C, Caron O, Fricker JP, Gladieff L, Faivre L, Sobol H, Gesta P, Frenay M, Luporsi E, Coupier I, Lidereau R, Andrieu N. Variation in breast cancer risk with mutation position, smoking, alcohol, and chest X-ray history, in the French National BRCA1/2 carrier cohort (GENEPSO) Breast Cancer Res Treat. 2011;14:927–938. doi: 10.1007/s10549-011-1655-3.
    1. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, Jack E, Vesprini DJ, Kuperstein G, Abrahamson JL, Fan I, Wong B, Narod SA. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;14:700–710. doi: 10.1086/318787.
    1. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, Tang J, Li S, Zhang S, Shaw PA, Narod SA. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst. 2006;14:1694–1706. doi: 10.1093/jnci/djj465.
    1. Evans DG, Shenton A, Woodward E, Lalloo F, Howell A, Maher ER. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer. 2008;14:155. doi: 10.1186/1471-2407-8-155.
    1. Begg CB, Haile RW, Borg A, Malone KE, Concannon P, Thomas DC, Langholz B, Bernstein L, Olsen JH, Lynch CF, Anton-Culver H, Capanu M, Liang X, Hummer AJ, Sima C, Bernstein JL. Variation of breast cancer risk among BRCA1/2 carriers. JAMA. 2008;14:194–201. doi: 10.1001/jama.2007.55-a.
    1. ENIGMA. (Evidence-based network for the interpretation of germline mutant alleles)
    1. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002;14:e57. doi: 10.1093/nar/gnf056.
    1. Casilli F, Di Rocco ZC, Gad S, Tournier I, Stoppa-Lyonnet D, Frebourg T, Tosi M. Rapid detection of novel BRCA1 rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragments. Hum Mutat. 2002;14:218–226. doi: 10.1002/humu.10108.
    1. Barrois M, Bieche I, Mazoyer S, Champeme MH, Bressac-de Paillerets B, Lidereau R. Real-time PCR-based gene dosage assay for detecting BRCA1 rearrangements in breast-ovarian cancer families. Clin Genet. 2004;14:131–136. doi: 10.1111/j.0009-9163.2004.00200.x.
    1. Rouleau E, Lefol C, Bourdon V, Coulet F, Noguchi T, Soubrier F, Bieche I, Olschwang S, Sobol H, Lidereau R. Quantitative PCR high-resolution melting (qPCR-HRM) curve analysis, a new approach to simultaneously screen point mutations and large rearrangements: application to MLH1 germline mutations in Lynch syndrome. Hum Mutat. 2009;14:867–875. doi: 10.1002/humu.20947.
    1. Weber J, Miserere S, Champ J, Looten R, Stoppa-Lyonnet D, Viovy JL, Houdayer C. High-throughput simultaneous detection of point mutations and large-scale rearrangements by CE. Electrophoresis. 2007;14:4282–4288. doi: 10.1002/elps.200700010.
    1. Gad S, Aurias A, Puget N, Mairal A, Schurra C, Montagna M, Pages S, Caux V, Mazoyer S, Bensimon A, Stoppa-Lyonnet D. Color bar coding the BRCA1 gene on combed DNA: a useful strategy for detecting large gene rearrangements. Genes Chromosomes Cancer. 2001;14:75–84. doi: 10.1002/gcc.1120.
    1. Rouleau E, Lefol C, Tozlu S, Andrieu C, Guy C, Copigny F, Nogues C, Bieche I, Lidereau R. High-resolution oligonucleotide array-CGH applied to the detection and characterization of large rearrangements in the hereditary breast cancer gene BRCA1. Clin Genet. 2007;14:199–207. doi: 10.1111/j.1399-0004.2007.00849.x.
    1. Antoniou AC, Goldgar DE, Andrieu N, Chang-Claude J, Brohet R, Rookus MA, Easton DF. A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. Genet Epidemiol. 2005;14:1–11. doi: 10.1002/gepi.20074.
    1. Negri E, La Vecchia C, Bruzzi P, Dardanoni G, Decarli A, Palli D, Parazzini F, Rosselli del TM. Risk factors for breast cancer: pooled results from three Italian case-control studies. Am J Epidemiol. 1988;14:1207–1215.
    1. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev. 1993;14:36–47.
    1. Beral V, Reeves G. Childbearing, oral contraceptive use, and breast cancer. Lancet. 1993;14:1102.
    1. Lambe M, Hsieh C, Trichopoulos D, Ekbom A, Pavia M, Adami HO. Transient increase in the risk of breast cancer after giving birth. N Engl J Med. 1994;14:5–9. doi: 10.1056/NEJM199407073310102.
    1. Antoniou AC, Shenton A, Maher ER, Watson E, Woodward E, Lalloo F, Easton DF, Evans DG. Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2006;14:R72. doi: 10.1186/bcr1630.
    1. Daling JR, Malone KE, Voigt LF, White E, Weiss NS. Risk of breast cancer among young women: relationship to induced abortion. J Natl Cancer Inst. 1994;14:1584–1592. doi: 10.1093/jnci/86.21.1584.
    1. Andrieu N, Duffy SW, Rohan TE, Le MG, Luporsi E, Gerber M, Renaud R, Zaridze DG, Lifanova Y, Day NE. Familial risk, abortion and their interactive effect on the risk of breast cancer--a combined analysis of six case-control studies. Br J Cancer. 1995;14:744–751. doi: 10.1038/bjc.1995.404.
    1. Rookus MA, Van Leeuwen FE. Induced abortion and risk for breast cancer: reporting (recall) bias in a Dutch case-control study. J Natl Cancer Inst. 1996;14:1759–1764. doi: 10.1093/jnci/88.23.1759.
    1. Russo J, Tay LK, Russo IH. Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat. 1982;14:5–73. doi: 10.1007/BF01805718.
    1. Vatten LJ, Romundstad PR, Trichopoulos D, Skjaerven R. Pregnancy related protection against breast cancer depends on length of gestation. Br J Cancer. 2002;14:289–290. doi: 10.1038/sj.bjc.6600453.
    1. Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA, Erdos M, Goldberg ID, Webb P, Kushner PJ, Pestell RG, Rosen EM. Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene. 2001;14:77–87. doi: 10.1038/sj.onc.1204073.
    1. Razandi M, Pedram A, Rosen EM, Levin ER. BRCA1 inhibits membrane estrogen and growth factor receptor signaling to cell proliferation in breast cancer. Mol Cell Biol. 2004;14:5900–5913. doi: 10.1128/MCB.24.13.5900-5913.2004.
    1. Cabanes A, Wang M, Olivo S, DeAssis S, Gustafsson JA, Khan G, Hilakivi-Clarke L. Prepubertal estradiol and genistein exposures up-regulate BRCA1 mRNA and reduce mammary tumorigenesis. Carcinogenesis. 2004;14:741–748.
    1. Ma H, Wang Y, Sullivan-Halley J, Weiss L, Marchbanks PA, Spirtas R, Ursin G, Burkman RT, Simon MS, Malone KE, Strom BL, McDonald JA, Press MF, Bernstein L. Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study. Cancer Res. 2010;14:575–587. doi: 10.1158/0008-5472.CAN-09-3460.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera